Announces that Marianne Stanford, PhD, has joined BioVaxys as Scientific Advisor. Dr Stanford was Vice President of R&D at the former IMV Inc, where she and her team were responsible for the development of the DPX™ vaccine portfolio. This included the study of the unique mechanism of action of the DPX platform and its safety, efficacy, and dosing schedules in preclinical models. BioVaxys Technology Corp shares C.BIOV are trading -$0.02 at $0.22.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BIOV%3ACC&qmodStoryID=6334284921101297
/Broadcom%20Inc%20logo%20on%20building-by%20Poetra_%20RH%20via%20Shutterstock.jpg)
/Nvidia%20logo%20on%20phone%20screen%20with%20stock%20chart%20by%20xalien%20via%20Shutterstock.jpg)
